542 The Dopamine Receptor D1(DRD1) as a target for Developinga Therapy for Cocaine Addiction Copy Right@ Jill Harp This work is licensed under Creative Commons Attribution 4.0 License AJBSR.MS.ID.002271. American Journal of Biomedical Science & Research www.biomedgrid.com --------------------------------------------------------------------------------------------------------------------------------- ISSN: 2642-1747 Research Article Jill Harp 1-5 * and Kiayia Propst 2 1 Department of Biological Sciences, Winston-Salem State University, USA 2 Center for Applied Data Science, Winston-Salem State University, USA 3 Department of Chemistry, Winston-Salem State University, USA 4 Biomedical Research Infrastructure Center, Winston-Salem State University, USA 5 Physiology and Pharmacology, Wake Forest University School of Medicine, USA *Corresponding author: Jill Harp, Winston-Salem State University Biomedical Research Infrastructure Center, USA. To Cite This Article: Jill Harp, Kiayia Propst. The Dopamine Receptor D1(DRD1) as Target for Developinga Therapy for Cocaine Addiction. Am J Biomed Sci & Res. 2022 - 16(5). AJBSR.MS.ID.002271. DOI: 10.34297/AJBSR.2022.16.002271 Received: June 25, 2022; Published: July 08, 2022 Introduction Cocaine is a crystalline tropane alkaloid that blocks the Dopamine (DA), norepinephrine, and serotonin reuptake transporters (DAT, NET, and SERT). Cocaine’s addictive properties are ascribed to the DA reward system and because it blocks the DAT, it generates higher than normal concentrations of DA in the synapse and causes euphoria [2]. Cocaine addiction, a global health problem, warrants the development of behavioral therapies and medication(s). The purpose of this study is to discover a cocaine replacement treatment that can be used with behavioral therapies. It is hypothesized that relationships can be predicted between drugs and disease by comparing gene expression data of healthy and addicted subjects and correlate the differences with gene expression data from FDA-approved drugs. These predictions should give rise to potential therapeutics based on this correlation. The DRD1 is the most abundant dopamine receptor subtype in the central nervous system. It is a G-protein coupled receptor that stimulates adenylyl cyclase and activates cyclic AMP-dependent Abstract It takes approximately fifteen years and nearly one billion dollars to bring a drug to market. A computational approach shows promise in being used to find therapeutics in less time and cost-effectively [1]. The approach reported herein mines publicly available gene expression data to uncover a gene is up or down regulated from microarray experiments and may lead to the repurposing of a current Food and Drug Administration (FDA)-approved drug to help cure cocaine addiction. Publicly available data from National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/) was used. Data sets were downloaded to uncover the gene expression difference between saline and cocaine-treated rats and the top genes analyzed. The secondary analysis included the correlation with FDA-approved drug gene expression data found on the Broad Institute’s Connectivity Map (CMap: https://clue.io/cmap) website. This resulted in the identification of compounds that antagonize the dopamine receptor D1(DRD1). Keywords: Connectivity Map, DRD1, Cocaine, Loxpine, Olanzapine, Clozapine, Gene Expression Abbreviations: NAcc: Nucleus Accumbency; DRD1: Dopamine Receptor Type 1; PFC: Prefrontal Cortex